Before we get into the details on Pfizer Inc, one micro cap company that is receiving great interest from Wall Street is CD International Enterprises, Inc. (CDII). Trading at mere 0.003, more than 25M shares have exchanged hands today and there could potentially be a buying frenzy. Here is the potential reason why more and more investors and traders would flock to CDII. Today, CDII filed its 8-K forms. As per the filing, On February 24, 2016, CD International Enterprises, Inc. (the “Company”) filed a complaint against three entities and two individuals in the District of Columbia, United States District Court. The complaint alleges illegal, unregistered resale of 220 million shares of restricted common stock of the Company. The Company seeks monetary recovery for damages for breach of contract and/or wrongful conversion of restricted shares; for damages arising from violations of Sections 5(a), 5(c) and 17(a) of the 1933 Securities Act, and Sections 10(b) and 12(b) of the 1934 Securities Act, and Rule 10b-5 promulgated thereunder. Monetary recovery includes monetary gain through fraud by defendants of over $2 million and loss of Companys market value of over $33 million. 

There could be a potential buy back from the investor mentioned in this complaint. So, keep an eyes on CDII.

At a time when getting approval from FDA has become an arduous task for many pharmaceutical companies, Pfizer Inc. (NYSE:PFE) announces yet another drug, which has received FDA’s approval. As per the reports, new XELJANZ XR, better known as tofacitinib citrate tablets, make the first and only available oral JAK inhibitor treatment for patients suffering from Rheumatoid Arthritis.

Insights of Matter

After U.S. Food & Drug Department’s approval, rheumatoid arthritis patients having an inadequate response to methotrexate can use these 11 mg tablets as the once-daily treatment and keep their disease under control. The launch of XELJANZ XR marks the first instance when a once-daily oral RA treatment in Janus kinase inhibitor class has been initiated.

The senior management team of the company is delighted to announce this update and hopes that it will change the way arthritis is perceived in medical science. According to Michael Corbo, Category Development Lead, Pfizer Global Innovative Pharmaceuticals Business, it’s another achievement that shows Pfizer’s leading position in immunology and inflammation fields. For many years, it’s been trying to build therapies according to patients’ needs, and the launch of JAK inhibitor for RA, XELJANZ XR is another step taken in the same direction.

Going forward, it will not only help patients but healthcare professionals as well. In the opinion of Dr. Roy Fleischmann from the University of Texas Southwestern Medical Center, as soon as the XELJANZ XR becomes available for commercial use, physicians will have an additional option for patients suffering from RA and wanting an oral-daily treatment.

It’s just the beginning of a new era that medical science is gradually moving towards with each passing year. The improved technology expanded research skills, and enhanced awareness of medical experts has forged the way for such developments that are result oriented and efficient for patients. Pfizer will continue to work on similar innovations in the coming months to ensure more such products can be launched in the future.